SKU: DHC404 | Published On: Feb 25 2021 | No. of Pages: 180 | Available Formats
The "Hepatitis A Vaccine Market" is expected to grow at a high CAGR of 2.8% during the forecasting period (2020-2027).
Hepatitis A Vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The Antibodies introduced in response to the disease lasts through life and protects against recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart.
Source: DataM Intelligence Analysis (2019)
The major factors propelling the growth of the Hepatitis A Vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in the risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.
Increasing Government Initiatives for Prevention
Hepatitis A Vaccine is used to submerge the rising cases for Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As per the World Health Organization, as of May 2019, the introduction of Hepatitis A vaccine in routine immunization of children in specific risk groups was used or planed by a total of 34 countries across the globe. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.
Lack of awareness among the population
Lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.
COVID-19 Impact Analysis
The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2020.
Hepatitis A Vaccine Market Segment Analysis
The Hepatitis A Vaccine market has been classified into Inactivated vaccine and a Live attenuated vaccine based on the Product Type type.
Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period.
Inactivated vaccine dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.
Hepatitis A Vaccine is segmented based on Application, which includes Government Institution, Private Sector and Other.
Government Institution is expected to dominate the Hepatitis A Vaccine market.
Government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.
Source: DataM Intelligence Analysis (2019)
Based on geography, the study analyzes the Hepatitis A Vaccine market globally, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market.
Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2019. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.
Source: DataM Intelligence Analysis (2019)
Hepatitis A Vaccine Market Competitive Landscape
The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine players contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.
HAVRIX (GlaxoSmithKline):
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastrointestinal, and skin health categories. The CET segment refers to the management of business activities. HAVRIX is a vaccine suitable for successful immunization of hepatitis A virus diseases (HAV). HAVRIX is licensed for use in people over the age of 12 months. At least 2 weeks before the planned exposure to HAV, primary immunization should be administered. The other Product Types offered by the company include Hepatyrix and Ambirix.
Product Type Portfolio: The company’s portfolio comprises a range of vaccines which includes Hepatitis A, Hepatitis B, Hepatitis C, among others
The global Hepatitis A Vaccine market report would provide access to an approx. 51 market data table, 45 figures and 221 pages.
Hepatitis Diagnostic Testing Market
List of Tables
Table 1 Global Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 2 Global Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 3 Global Hepatitis A Vaccine Market Value, By Region, 2019, 2023 & 2027 (US$ Million)
Table 4 North America Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 5 North America Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 6 North America Hepatitis A Vaccine Market Value, By Country, 2018-2027 (US$ Million)
Table 7 South America Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 8 South America Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 9 South America Hepatitis A Vaccine Market Value, By Country, 2018-2027 (US$ Million)
Table 10 Europe Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 11 Europe Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 12 Europe Hepatitis A Vaccine Market Value, By Country, 2018-2027 (US$ Million)
Table 13 Asia Pacific Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 14 Asia Pacific Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 15 Asia Pacific Hepatitis A Vaccine Market Value, By Country, 2019, 2023 & 2027 (US$ Million)
Table 16 The Middle East & Africa Hepatitis A Vaccine Market Value, By Product Type, 2019, 2023 & 2027 (US$ Million)
Table 17 The Middle East & Africa Hepatitis A Vaccine Market Value, By Application, 2019, 2023 & 2027 (US$ Million)
Table 18 The Middle East & Africa Hepatitis A Vaccine Market Value, By Country, 2019, 2023 & 2027 (US$ Million)
Table 19 GlaxoSmithKline : Overview
Table 20 GlaxoSmithKline : Product Type Portfolio
Table 21 GlaxoSmithKline : Key Developments
Table 22 Merck & Co., Inc. : Overview
Table 23 Merck & Co., Inc. : Product Type Portfolio
Table 24 Merck & Co., Inc. : Key Developments
Table 25 Sanofi : Overview
Table 26 Sanofi : Product Type Portfolio
Table 27 Sanofi : Key Developments
Table 28 Sinovac: Overview
Table 29 Sinovac: Product Type Portfolio
Table 30 Sinovac: Key Developments
Table 31 Zhejiang Pukang: Overview
Table 32 Zhejiang Pukang: Product Type Portfolio
Table 33 Zhejiang Pukang: Key Developments
Table 34 Changchun Institute of Biological: Overview
Table 35 Changchun Institute of Biological: Product Type Portfolio
Table 36 Changchun Institute of Biological: Key Developments
Table 37 KM BIOLOGICS: Overview
Table 38 KM BIOLOGICS: Product Type Portfolio
Table 39 KM BIOLOGICS: Key Developments
Table 40 IMBCA: Overview
Table 41 IMBCA: Product Type Portfolio
Table 42 IMBCA: Key Developments
Table 43 CHANGSHENG: Overview
Table 44 CHANGSHENG: Product Type Portfolio
Table 45 CHANGSHENG: Key Developments
Table 46 Convac: Overview
Table 47 Convac: Product Type Portfolio
Table 48 Convac: Key Developments
List of Figures
Figure 1 Global Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 2 Global Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 3 Global Hepatitis A Vaccine Market Share, By Region, 2019 & 2027 (%)
Figure 4 Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 5 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Product Type, 2019-2027 (%)
Figure 6 Inactivated Vaccine: Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 7 Live Attenuated Vaccine: Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 8 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Application, 2019-2027 (%)
Figure 9 Government Institution: Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 10 Private Sector: Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 11 Other: Global Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 12 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Region, 2019-2027 (%)
Figure 13 North America Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 14 North America Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 15 North America Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 16 North America Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 17 North America Hepatitis A Vaccine Market Share, By Country, 2019 & 2027 (%)
Figure 18 South America Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 19 South America Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 20 South America Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 21 South America Hepatitis A Vaccine Market Share, By Country, 2019 & 2027 (%)
Figure 22 Europe Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 23 Europe Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 24 Europe Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 25 Europe Hepatitis A Vaccine Market Share, By Country, 2019 & 2027 (%)
Figure 26 Asia-Pacific Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 27 Asia-Pacific Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 28 Asia-Pacific Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 29 Asia-Pacific Hepatitis A Vaccine Market Share, By Country, 2019 & 2027 (%)
Figure 30 The Middle East & Africa Hepatitis A Vaccine Market Value, 2018-2027 (US$ Million)
Figure 31 The Middle East & Africa Hepatitis A Vaccine Market Share, By Product Type, 2019 & 2027 (%)
Figure 32 The Middle East & Africa Hepatitis A Vaccine Market Share, By Application, 2019 & 2027 (%)
Figure 33 The Middle East & Africa Hepatitis A Vaccine Market Share, By Country, 2019 & 2027 (%)
Figure 34 GlaxoSmithKline: Financials
Figure 35 Merck & Co., Inc.: Financials
Figure 36 Sanofi: Financials
Figure 37 Sinovac: Financials
Figure 38 Zhejiang Pukang: Financials
Figure 39 Changchun Institute of Biological: Financials
Figure 40 KM BIOLOGICS: Financials
Figure 41 IMBCA: Financials
Figure 42 CHANGSHENG: Financials
Figure 43 Convac: Financials
Get your FREE SAMPLE PROPOSAL with a single click!